Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
NCT06055322
Alzheimer Disease, Behavior
Lubbock, Texas, United States
View Trial DetailsNCT Number: NCT00763724
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for depression, patients treated with one of three other antidepressants or antidepressant classes (venlafaxine, SSRIs, or TCAs) for depression, patients treated with multiple antidepressants for depression (either concurrently or consecutively), depressed patients with no pharmacologic treatment, and a non-depressed general population sample.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Endpoint
Time frame: Endpoint
Eli Lilly and Company
Industry
A Propensity-Matched Retrospective Cohort Study of Antidepressant Drug Exposure and Risk of Suicide Attempt in Adults From a Large U.S. Managed Care Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06055322
Alzheimer Disease, Behavior
Lubbock, Texas, United States
View Trial DetailsNCT04506164
Behavior, Behavioral Symptoms
San Diego, California, United States
View Trial DetailsNCT03868930
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT05021224
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial Details